Effect of palmitoylethanolamide on visual field damage progression in normal tension glaucoma patients

Results of an open-label six-month follow-up

Ciro Costagliola, Mario R. Romano, Roberto Dell'Omo, Andrea Russo, Rodolfo Mastropasqua, Francesco Semeraro

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

The purpose of this study is to assess the effect of palmitoylethanolamide (PEA) oral administration on intraocular pressure (IOP) and visual field damage progression in normal-tension glaucoma (NTG) patients. Thirty-two consecutive patients affected by NTG were enrolled and randomized in a 1:1 ratio to receive PEA treatment (group A) or no treatment (group B). Group A patients took ultramicronized 300mg PEA tablets two times per day for six months. Best-corrected visual acuity (BCVA), IOP, and visual field test were evaluated at baseline and at the end of the six-month follow-up. No significant differences in clinical parameters between the two groups were observed at baseline. At six months, group A patients showed significant IOP reduction (from 14.4±3.2mm Hg to 11.1±4.3mm Hg, p

Original languageEnglish
Pages (from-to)949-954
Number of pages6
JournalJournal of Medicinal Food
Volume17
Issue number9
DOIs
Publication statusPublished - Sep 1 2014

Fingerprint

Low Tension Glaucoma
Visual Fields
Intraocular Pressure
Visual Field Tests
Tablets
Visual Acuity
Oral Administration
palmidrol
Therapeutics

Keywords

  • glaucoma progression
  • intraocular pressure
  • normal tension glaucoma
  • palmitoylethanolamide
  • visual field

ASJC Scopus subject areas

  • Medicine (miscellaneous)
  • Nutrition and Dietetics
  • Medicine(all)

Cite this

Effect of palmitoylethanolamide on visual field damage progression in normal tension glaucoma patients : Results of an open-label six-month follow-up. / Costagliola, Ciro; Romano, Mario R.; Dell'Omo, Roberto; Russo, Andrea; Mastropasqua, Rodolfo; Semeraro, Francesco.

In: Journal of Medicinal Food, Vol. 17, No. 9, 01.09.2014, p. 949-954.

Research output: Contribution to journalArticle

Costagliola, Ciro ; Romano, Mario R. ; Dell'Omo, Roberto ; Russo, Andrea ; Mastropasqua, Rodolfo ; Semeraro, Francesco. / Effect of palmitoylethanolamide on visual field damage progression in normal tension glaucoma patients : Results of an open-label six-month follow-up. In: Journal of Medicinal Food. 2014 ; Vol. 17, No. 9. pp. 949-954.
@article{1f43bd5a9fcf433cb7c51979e2c80d61,
title = "Effect of palmitoylethanolamide on visual field damage progression in normal tension glaucoma patients: Results of an open-label six-month follow-up",
abstract = "The purpose of this study is to assess the effect of palmitoylethanolamide (PEA) oral administration on intraocular pressure (IOP) and visual field damage progression in normal-tension glaucoma (NTG) patients. Thirty-two consecutive patients affected by NTG were enrolled and randomized in a 1:1 ratio to receive PEA treatment (group A) or no treatment (group B). Group A patients took ultramicronized 300mg PEA tablets two times per day for six months. Best-corrected visual acuity (BCVA), IOP, and visual field test were evaluated at baseline and at the end of the six-month follow-up. No significant differences in clinical parameters between the two groups were observed at baseline. At six months, group A patients showed significant IOP reduction (from 14.4±3.2mm Hg to 11.1±4.3mm Hg, p",
keywords = "glaucoma progression, intraocular pressure, normal tension glaucoma, palmitoylethanolamide, visual field",
author = "Ciro Costagliola and Romano, {Mario R.} and Roberto Dell'Omo and Andrea Russo and Rodolfo Mastropasqua and Francesco Semeraro",
year = "2014",
month = "9",
day = "1",
doi = "10.1089/jmf.2013.0165",
language = "English",
volume = "17",
pages = "949--954",
journal = "Journal of Medicinal Food",
issn = "1096-620X",
publisher = "Mary Ann Liebert Inc.",
number = "9",

}

TY - JOUR

T1 - Effect of palmitoylethanolamide on visual field damage progression in normal tension glaucoma patients

T2 - Results of an open-label six-month follow-up

AU - Costagliola, Ciro

AU - Romano, Mario R.

AU - Dell'Omo, Roberto

AU - Russo, Andrea

AU - Mastropasqua, Rodolfo

AU - Semeraro, Francesco

PY - 2014/9/1

Y1 - 2014/9/1

N2 - The purpose of this study is to assess the effect of palmitoylethanolamide (PEA) oral administration on intraocular pressure (IOP) and visual field damage progression in normal-tension glaucoma (NTG) patients. Thirty-two consecutive patients affected by NTG were enrolled and randomized in a 1:1 ratio to receive PEA treatment (group A) or no treatment (group B). Group A patients took ultramicronized 300mg PEA tablets two times per day for six months. Best-corrected visual acuity (BCVA), IOP, and visual field test were evaluated at baseline and at the end of the six-month follow-up. No significant differences in clinical parameters between the two groups were observed at baseline. At six months, group A patients showed significant IOP reduction (from 14.4±3.2mm Hg to 11.1±4.3mm Hg, p

AB - The purpose of this study is to assess the effect of palmitoylethanolamide (PEA) oral administration on intraocular pressure (IOP) and visual field damage progression in normal-tension glaucoma (NTG) patients. Thirty-two consecutive patients affected by NTG were enrolled and randomized in a 1:1 ratio to receive PEA treatment (group A) or no treatment (group B). Group A patients took ultramicronized 300mg PEA tablets two times per day for six months. Best-corrected visual acuity (BCVA), IOP, and visual field test were evaluated at baseline and at the end of the six-month follow-up. No significant differences in clinical parameters between the two groups were observed at baseline. At six months, group A patients showed significant IOP reduction (from 14.4±3.2mm Hg to 11.1±4.3mm Hg, p

KW - glaucoma progression

KW - intraocular pressure

KW - normal tension glaucoma

KW - palmitoylethanolamide

KW - visual field

UR - http://www.scopus.com/inward/record.url?scp=84906983304&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84906983304&partnerID=8YFLogxK

U2 - 10.1089/jmf.2013.0165

DO - 10.1089/jmf.2013.0165

M3 - Article

VL - 17

SP - 949

EP - 954

JO - Journal of Medicinal Food

JF - Journal of Medicinal Food

SN - 1096-620X

IS - 9

ER -